Past Coverage of ACR 2014Past Coverage of ACR 2014 Return To RheumReports Home

 

Scleroderma Session is Standing Room Only!

November 17 2014 1:36 PM ET via RheumReports RheumReports

This may be a first for scleroderma where a concurrent session was over full. 

Two positive early phase RCTs were presented – Tocilizumab vs. monotherapy in early diffuse systemic sclerosis (#874) where both the 24 and 48 week data were presented showing a decrease in modified Rodnan skin score and some other outcomes, and SAR100842 (a lysophosphatidic acid (LPA) antagonist) (#876) yesterday afternoon. In the latter small trial, the skin score also decreased very quickly and when placebo crossed over to active treatment, this effect was reproduced as was expected. 

Scleroderma has some treatment options for ILD and PAH, and if an overall disease modifying drug could be developed, it would be embraced. Like all early stage development programs, time will tell.


Share This Report


About the Author

Dr. Janet Pope
Dr. Janet Pope

Dr. Janet Pope is Professor of Medicine at Western University and Division Head of Rheumatology. Dr. Pope's research interests include epidemiologic studies in scleroderma, classification criteria in systemic sclerosis, systemic lupus erythematosus and rheumatoid arthritis.

View Full Bio

Trending Reports From ACR 2014